North America Dry Eye Disease Market Forecast 2024-2032

North America Dry Eye Disease Market Forecast 2024-2032

The North America dry eye disease market is expected to grow at a CAGR of 5.12% during the forecast period of 2024 to 2032. The market was valued at $2283.72 million in 2032, reaching a projected revenue of $3604.57 million by 2032.

MARKET INSIGHTS

The rising geriatric population in North America is a significant factor contributing to the growing number of cases of dry eye diseases. Older individuals are more prone to conditions affecting tear production, leading to common dry eye disease symptoms such as dryness, burning, and blurred vision. Environmental factors and lifestyle changes, including increased screen time, are also contributing to the increasing prevalence of dry eye disease across all age groups.

REGIONAL ANALYSIS

The North America dry eye disease market growth analysis includes a detailed examination of the United States and Canada. Technological advancements in therapeutic and diagnostic products are facilitating more effective treatment for dry eye disease. New dry eye disease treatment drugs and products, including artificial tears and anti-inflammatory medications, are improving patient outcomes. Moreover, the demand for dry eye disease treatment devices is on the rise, as these devices help enhance tear production and alleviate symptoms. Innovations in eye drops and treatment technologies are addressing the need for more efficient and targeted solutions.

In the United States, a National Health and Wellness Survey reports that 6.8% of the adult population is affected by dry eye disease, with prevalence increasing with age and being higher in females compared to males. Further analysis from the 2017 National Health and Wellness Survey (NHWS) indicates that the gender disparity in dry eye disease prevalence widens as age increases. Consequently, healthcare professionals expect a rise in cases of dry eye syndrome among the aging population.

Additionally, product launches and innovations by major companies are poised to boost market opportunities. For example, in 2022, Bausch + Lomb presented data from a second pivotal Phase 3 trial for their investigational treatment, NOV03. This would be the first pharmaceutical therapy in the United States featuring a new mechanism of action specifically targeting the relief of dry eye symptoms related to Meibomian gland dysfunction.

SEGMENTATION ANALYSIS

The North America dry eye disease market segmentation includes type, product, dosage, and distribution channel. The type segment is further classified into OTC and prescription.

Over-the-counter (OTC) treatments, including artificial tears and lubricating eye drops, are widely used products by patients for quick relief from dry eye disease symptoms. Leading players in this segment include Johnson & Johnson, which provides a variety of eye care products aimed at addressing dry eye symptoms. Companies such as Alcon and Allergan PLC also play a significant role in the OTC segment with their range of treatments for dry eye disease.

While the demand for anti-inflammatory drugs and treatment devices continues to rise, one of the challenges facing the market is the underdiagnosis of dry eye disease. Many patients remain unaware of their condition or do not seek proper treatment. However, increasing awareness through educational initiatives and improved access to diagnostic tools are expected to boost diagnosis rates, allowing for more effective management of the disease.

COMPETITIVE INSIGHTS

Some of the key firms operating in the North America dry eye disease market are Novartis AG, Novaliq GmbH, Lumenis, Oasis Medical, etc.

Oasis Medical Inc, headquartered in Los Angeles, California, is a specialized manufacturer of surgical supplies, instruments, disposables, and eye care products. The company produces a wide range of products aimed at treating retinal diseases, dry eye disease, refractive errors, and cataracts. One of its flagship products, Oasis TEARS® PF PLUS Preservative-Free Lubricant Eye Drops, is designed to combat dry eye, offering viscoadaptive properties and strong adherence for effective relief.KEY FINDINGS The North America dry eye disease market is expected to grow at a CAGR of 5.12% during the forecast period of 2024 to 2032. The market was valued at $2283.72 million in 2032, reaching a projected revenue of $3604.57 million by 2032. MARKET INSIGHTS The rising geriatric population in North America is a significant factor contributing to the growing number of cases of dry eye diseases. Older individuals are more prone to conditions affecting tear production, leading to common dry eye disease symptoms such as dryness, burning, and blurred vision. Environmental factors and lifestyle changes, including increased screen time, are also contributing to the increasing prevalence of dry eye disease across all age groups. REGIONAL ANALYSIS The North America dry eye disease market growth analysis includes a detailed examination of the United States and Canada. Technological advancements in therapeutic and diagnostic products are facilitating more effective treatment for dry eye disease. New dry eye disease treatment drugs and products, including artificial tears and anti-inflammatory medications, are improving patient outcomes. Moreover, the demand for dry eye disease treatment devices is on the rise, as these devices help enhance tear production and alleviate symptoms. Innovations in eye drops and treatment technologies are addressing the need for more efficient and targeted solutions. In the United States, a National Health and Wellness Survey reports that 6.8% of the adult population is affected by dry eye disease, with prevalence increasing with age and being higher in females compared to males. Further analysis from the 2017 National Health and Wellness Survey (NHWS) indicates that the gender disparity in dry eye disease prevalence widens as age increases. Consequently, healthcare professionals expect a rise in cases of dry eye syndrome among the aging population. Additionally, product launches and innovations by major companies are poised to boost market opportunities. For example, in 2022, Bausch + Lomb presented data from a second pivotal Phase 3 trial for their investigational treatment, NOV03. This would be the first pharmaceutical therapy in the United States featuring a new mechanism of action specifically targeting the relief of dry eye symptoms related to Meibomian gland dysfunction. SEGMENTATION ANALYSIS The North America dry eye disease market segmentation includes type, product, dosage, and distribution channel. The type segment is further classified into OTC and prescription. Over-the-counter (OTC) treatments, including artificial tears and lubricating eye drops, are widely used products by patients for quick relief from dry eye disease symptoms. Leading players in this segment include Johnson & Johnson, which provides a variety of eye care products aimed at addressing dry eye symptoms. Companies such as Alcon and Allergan PLC also play a significant role in the OTC segment with their range of treatments for dry eye disease. While the demand for anti-inflammatory drugs and treatment devices continues to rise, one of the challenges facing the market is the underdiagnosis of dry eye disease. Many patients remain unaware of their condition or do not seek proper treatment. However, increasing awareness through educational initiatives and improved access to diagnostic tools are expected to boost diagnosis rates, allowing for more effective management of the disease. COMPETITIVE INSIGHTS Some of the key firms operating in the North America dry eye disease market are Novartis AG, Novaliq GmbH, Lumenis, Oasis Medical, etc. Oasis Medical Inc, headquartered in Los Angeles, California, is a specialized manufacturer of surgical supplies, instruments, disposables, and eye care products. The company produces a wide range of products aimed at treating retinal diseases, dry eye disease, refractive errors, and cataracts. One of its flagship products, Oasis TEARS® PF PLUS Preservative-Free Lubricant Eye Drops, is designed to combat dry eye, offering viscoadaptive properties and strong adherence for effective relief.

Please Note: Report delivered with PDF + Excel